← Back to Search

Telemedicine for Hepatitis C Management

N/A

Waitlist Available

Led By Andrew H Talal, MD

Research Sponsored by Andrew Talal

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 210 weeks

Awards & highlights

Study Summary

This trial will compare the effectiveness of a telemedicine-based approach to usual care for treating hepatitis C in people with substance use disorders. The primary outcome will be viral eradication, defined as undetectable HCV RNA 12 weeks after treatment stops.

Who is the study for?

This trial is for adults over 18 with Hepatitis C who are on methadone treatment for at least a year, willing to consent, and have medical insurance. It's not for those already being treated for HCV, lacking mental competence, uninsured, likely non-adherent to treatments or enrolled in methadone treatment less than a year.Check my eligibility

What is being tested?

The study tests if managing Hepatitis C through telemedicine integrated with opiate agonist treatment is as effective as usual care (likely offsite referrals). Success is measured by the absence of HCV RNA in blood tests taken 12 weeks after stopping treatment.See study design

What are the potential side effects?

Since this trial focuses on the delivery method (telemedicine) rather than a new medication, side effects relate more to technical issues or personal comfort with remote communication rather than typical drug side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 210 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 210 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 210 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of patients in both arms who achieve viral eradication

Secondary outcome measures

Comparison of patient satisfaction

Comparison of treatment completion rates

Comparison of treatment initiation rates

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: InterventionExperimental Treatment1 Intervention

Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)

Group II: ControlActive Control1 Intervention

Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Patient-Centered Outcomes Research InstituteOTHER

554 Previous Clinical Trials

29,948,777 Total Patients Enrolled

4 Trials studying Hepatitis C

37,115 Patients Enrolled for Hepatitis C

Andrew TalalLead Sponsor

Andrew H Talal, MDPrincipal InvestigatorSUNY Buffalo

Media Library

Telemedicine Clinical Trial Eligibility Overview. Trial Name: NCT02933970 — N/A

Hepatitis C Research Study Groups: Control, Intervention

Hepatitis C Clinical Trial 2023: Telemedicine Highlights & Side Effects. Trial Name: NCT02933970 — N/A

Telemedicine 2023 Treatment Timeline for Medical Study. Trial Name: NCT02933970 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots left for enrolment in this clinical study?

"The information accessible from clinicaltrials.gov implies that this trial is not presently enrolling participants, having been initially posted on February 28th 2017 and last edited on November 1st 2022. However, there are 97 other medical studies accepting volunteers at the present moment."

Answered by AI

Recent research and studies

Telemedicine and e-HealthJournal

High Satisfaction with Patient-centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-methods Study

Talal, Andrew H., Elisavet M. Sofikitou, Kejia Wang, Suzanne Dickerson, Urmo Jaanimägi, and Marianthi Markatou. 2022. “High Satisfaction with Patient-centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-methods Study”. Telemedicine and E-health. Mary Ann Liebert Inc. doi:10.1089/tmj.2022.0189.

clinicaltrials.govStudy

Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals

Andrew Talal 2017. "Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02933970.